SARS-CoV-2: From Virus Replication Cycle to Antiviral Strategies
A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Viral Pathogens".
Deadline for manuscript submissions: closed (15 December 2023) | Viewed by 8933
Special Issue Editor
Interests: influenza A virus; emerging viruses; virus–host cell interactions; virus entry; antivirals
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
SARS-CoV-2 has already infected 263 million people and the ongoing COVID-19 pandemic has killed more than 5 million people worldwide. To prevent further deaths and minimize the socio-economic burden, the global population must be vaccinated and acquire herd immunity. However, it needs to be highlighted that vaccine effectiveness and protection can be low in some groups (i.e., ‘vaccine non-responders’, immunocompromised patients), and these people can develop severe COVID-19. Moreover, considering the relatively low proportion of vaccinated people, there is a risk of the emergence of new potential vaccine-resistant SARS-CoV-2 strains. Therefore, in addition to vaccination, efficient drugs for COVID-19 treatment need to be developed.
Knowledge of the viral replication cycle and virus–host interaction is key to developing novel antivirals. Thus, this Pathogens Special Issue will focus on SARS-CoV-2 biology, including virus entry, replication, assembly and release, as well as SARS-CoV-2–host cell interactions, and potential implications for the development of novel antiviral strategies.
Dr. Pawel Zmora
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- SARS-CoV-2
- virus entry
- virus replication
- virus assembly and budding
- antivirals
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.